| Sep 16 |
J&J’s Shockwave strengths IVL grasp with new US catheter launch
|
| Sep 16 |
ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact
|
| Sep 16 |
Johnson & Johnson’s RYBREVANT trial shows improved response rate
|
| Sep 16 |
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
|
| Sep 15 |
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
|
| Sep 14 |
J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report
|
| Sep 14 |
Is Johnson & Johnson (JNJ) the Best Blue Chip Stock To Invest In According to Short Sellers?
|
| Sep 14 |
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
|
| Sep 14 |
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
|
| Sep 13 |
How Much Would It Take To Earn $1,000 A Month In Dividends With Just Four Stocks?
|
